Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

Compass Pathways reports that its synthetic psilocybin candidate COMP360 cleared the first Phase 3 checkpoint in treatment-resistant depression (TRD), with the 25mg arm separating from placebo. The readout centers on a statistically significant 3.6-point between-group difference on the MADRS at week 6 (primary endpoint) and a Data and Safety Monitoring Board (DSMB) finding of no new or unexpected safety issues, including no clinically meaningful imbalance in suicidality between arms. The article emphasizes that this topline result is limited by the placebo-controlled design and regulatory expectations, so it provides more of a safety and separation signal than a full efficacy picture. Attention then turns to the larger second Phase 3 study (COMP006), expected to read out in the second half of 2026, with a multi-dose design intended to clarify efficacy and refine the safety profile for a potential U.S. launch.